NewAmsterdam Pharma Company, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on the stock and has a $52.00 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight NewAmsterdam Pharma Company’s promising future. The company is actively building a global infrastructure to support its potential transition to a commercial stage, which is a positive indicator for its growth prospects. Additionally, Pantginis is optimistic about the upcoming PREVAIL CVOT data expected by the end of 2026, which is supported by an optimal study design and encouraging early data from previous studies.
Furthermore, NewAmsterdam’s financial position is strong, with $756 million in cash, providing a solid foundation for future developments. The company’s ongoing research and development efforts, particularly with its obicetrapib R&D franchise, are progressing well. The acceptance of obicetrapib monotherapy and combination therapies for review by the EMA, along with the initiation of new trials, underscores the company’s commitment to expanding its clinical profile and exploring new treatment combinations. These strategic moves are expected to enhance NewAmsterdam’s market position and open up new opportunities in the cardiometabolic and neurovascular fields.
In another report released on October 20, Citi also maintained a Buy rating on the stock with a $50.00 price target.